Biagio Barbano

Biagio Barbano

Auto-generated profile, based on publicly available information

Biagio Barbano

Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2013 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
AGAntonietta Gigante
Antonietta Gigante
AAAntonio Amoroso
Antonio Amoroso
RCRosario Cianci
Rosario Cianci
BBBiagio Barbano
Biagio Barbano
Nephrotic syndrome (NS) is characterized by heavy proteinuria, edema, hypoalbuminemia, and hyperlipidemia and the most frequent causes are glomerular diseases. An uncommon presentation is iatrogenic NS, an adverse effect of some drugs administration. In the clinical course of NS, a typical feature is dysregulated coagulation state, promoted by the breakdown of permselectivity barrier of the glomerular capillary wall, resulting in the leakage of high-molecular-mass proteins, at least the size of albumin. This hypercoagulable condition is supported by several factors, such as abnormalities in platelet activation and an imbalance between anticoagulation/antithrombosis and procoagulant/prothrombotic mechanisms. Thus, NS and the risk of developing thromboses are strictly related. Thrombotic events affect the venous system rather than arterial vessels with different features and frequencies. Deep venous system of the lower extremities and renal veins are the most frequent source of pulmonary embolism, the most dangerous NS complication. Prophylactic anticoagulation and thrombosis treatment are not clearly established because large randomized trials and guidelines are lacking. The management of NS and the decision of when and how to anticoagulate the patient represent a teamwork challenge for physicians.

31 May 2014 in Current Vascular Pharmacology
Verified
Journal Article
Closed access
PDF file
AGAntonietta Gigante
Antonietta Gigante
BBBiagio Barbano
Biagio Barbano
LSLiborio Sardo
Liborio Sardo
PMPaola Martina
Paola Martina
MGMaria L. Gasperini
Maria L. Gasperini
RCRosario Cianci
Rosario Cianci
Patients with nephrotic syndrome are at increased risk for thromboembolic events such as deep venous and arterial thrombosis, renal vein thrombosis and pulmonary embolism. This thrombophilic phenomenon has been attributed to a “hypercoagulable” state in which an imbalance between naturally occurring pro-coagulant/pro-thrombotic factors and anti-coagulant/antithrombotic factors promotes in situ thrombosis in deep veins or arteries. Management of thromboembolic events may be divided in prophylactic and therapeutic strategies. Hypoalbuminemia is the most significant independent predictor factor of thrombotic risk, especially for values <2 g/dL. However, the most important question in these patients is whether to anticoagulate prophylactically or not. The decision depends on type of glomerulonephritis, proteinuria severity, other predisposing factors and prior history of thrombosis. Reviewing the recent literature, we suggest the best therapeutic management of anticoagulation for patients with nephrotic syndrome, focusing on prophylactic strategies.

1 November 2017 in Microvascular Research
Verified
Journal Article
Closed access
AGAntonietta Gigante
Antonietta Gigante
NLNavarini Luca
Navarini Luca
DMDomenico Margiotta
Domenico Margiotta
AAAntonio Amoroso
Antonio Amoroso
BBBiagio Barbano
Biagio Barbano
Edoardo RosatoEdoardo Rosato
Edoardo Rosato

24 March 2016 in Current Drug Metabolism
Verified
Journal Article
Closed access
RPRiccardo Pofi
Riccardo Pofi
FMFrancesca Di Mario
Francesca Di Mario
AGAntonietta Gigante
Antonietta Gigante
Edoardo RosatoEdoardo Rosato
Edoardo Rosato
AIAndrea M. Isidori
Andrea M. Isidori
BBBiagio Barbano
Biagio Barbano
Background: Diabetic nephropathy (DN) is currently the most common cause of end-stage renal disease (ESRD). Although nowadays much is known about its classification, pathogenesis, clinical manifestations and evolution, to date we are not yet able to stop the natural progression of nephropathy in diabetic patients. Methods: Treatment options are: lifestyle change with close blood pressure monitoring and tight glycemic control. The most common therapies adopted for this condition are Angiotensing Converting Enzyme-inhibitors (ACEi). However these drugs are able to block the progression of renal damage only in a small proportion of patients. In the remaining, DN progresses and may evolve into ESRD. Conclusion: The purpose of this review is to summarize the “state of art” of current novel therapeutic strategies to stem this debilitating kidney disease.

31 March 2014 in Current Vascular Pharmacology
Verified
Journal Article
Closed access
PDF file
BBBiagio Barbano
Biagio Barbano
LSLiborio Sardo
Liborio Sardo
AGAntonietta Gigante
Antonietta Gigante
MGMaria Ludovica Gasperini
Maria Ludovica Gasperini
MLMarta Liberatori
Marta Liberatori
RCRosario Cianci
Rosario Cianci
Advanced cirrhosis is frequently associated with renal dysfunction. Hepatorenal syndrome (HRS) is characterized by the occurrence of kidney injury in cirrhotic patients in the absence of other identifiable causes. HRS is classified in 2 different types. Type 1 is characterized by acute renal failure and rapid functional deterioration of other organs, usually related to a precipitating event. Type 2 is characterized by slowly progressive renal failure and refractory ascites. Advanced liver disease induces the progression of hemodynamic alterations such as arterial vasodilation of splanchnic circulation and impairment of cardiac function. The resulting ineffective circulating blood volume promotes the activation of both the renin-angiotensin-aldosterone and sympathetic nervous system, by an increase of antidiuretic hormone activity, in an attempt to restore volemia. Despite fluid retention, ascites and dilutional hyponatremia, renal function is often initially preserved by renal production of vasodilators. However, further insults can lead to an imbalance between systemic vasoconstriction and local renal vasodilation, resulting in progressive renal failure. Over the last decade, clinical strategies to prevent HRS have been improved by a better understanding of the natural history of renal failure in cirrhosis, resulting in a reduction of HRS prevalence in cirrhotic patients. Vasoconstrictor drugs may improve renal function, but the effect on mortality has not yet been established. Vaptans, nonpeptide vasopressin receptor antagonists, may also reduce hyponatraemia and ascites, even if the clinical effects in HRS remain unknown. This review updates the pathophysiology, diagnosis and management of HRS.

1 March 2017 in Microvascular Research
Verified
Journal Article
Closed access
BBBiagio Barbano
Biagio Barbano
AMAlessandro Maria Marra
Alessandro Maria Marra
SQSilvia Quarta
Silvia Quarta
AGAntonietta Gigante
Antonietta Gigante
GBGiuseppe Barilaro
Giuseppe Barilaro
Edoardo RosatoEdoardo Rosato
Edoardo Rosato